Study Evaluating EKB-569 in Advanced Non-Small Cell Lung Cancer
NCT00067548
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
44
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-Small-Cell Lung Carcinoma
Carcinoma, Non-Small Cell Lung
Lung Neoplasms
Interventions
DRUG:
EKB-569
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer